Mohammad Khan
Rheumatology · Oklahoma City, OKNPI 1699822379
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $74,554 of the $93,967 with a category attached, or 79.3%. 25 manufacturers reported payments, led by AbbVie at 31.3% of the total. Reporting peaked in 2019 at $54,712 and has fallen 100.0% since, to $23 in 2024. Among rheumatology clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 639 payments — averaging $147.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$29K
- Amgen$22K
- E.r. Squibb & Sons, L.L.C.$20K
- Novartis$8K
- Pfizer$5K
- UCB, Inc.$4K
- plus $5K from 19 others
Across 75 payments — averaging $12,089 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$335K
- Eli Lilly$333K
- GSK$64K
- Pfizer$56K
- Amgen$46K
- E.r. Squibb & Sons, L.L.C.$32K
- plus $41K from 6 others
What the payments were for
- Consulting fees$4,5005%
- Speaking & faculty fees$74,55479%
- Travel & lodging$4,7565%
- Food & beverage$9,95211%
- Education$2060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 113 | $29,412 |
| Amgen(2 entities) | 127 | $22,132 |
| E.r. Squibb & Sons, L.L.C. | 58 | $19,761 |
| Novartis | 33 | $8,256 |
| Pfizer | 49 | $5,119 |
| UCB, Inc. | 71 | $4,074 |
| Aurinia Pharma U.S., Inc. | 3 | $2,107 |
| Sanofi | 26 | $679 |
| Lilly USA, LLC | 31 | $448 |
| GSK | 29 | $364 |
| Genentech USA, Inc. | 18 | $247 |
| Mallinckrodt Hospital Products Inc. | 17 | $216 |
| Radius Health, Inc. | 12 | $207 |
| Johnson & Johnson | 12 | $191 |
| Antares Pharma, Inc. | 10 | $156 |
| Mallinckrodt Enterprises LLC | 9 | $151 |
| Sanofi-aventis U.S. LLC | 2 | $106 |
| Zyla Life Sciences, Inc. | 6 | $82 |
| Actelion Pharmaceuticals US, Inc. | 3 | $70 |
| Nalu Medical, Inc. | 1 | $61 |
| AstraZeneca | 4 | $56 |
| Merck | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,967 in reported general payments places this provider in the 95th percentile of 67 rheumatology providers in Oklahoma.
Other rheumatology in Oklahoma City
- Joan MerrillOklahoma City$864K
- Latisha HeinlenOklahoma City$675K
- Cristina ArriensOklahoma City$82K
- John GoetzingerOklahoma City$18K
- Robert ArthurOklahoma City$16K
- Muhammad GillanOklahoma City$16K
- William SchnitzOklahoma City$15K
- Judith JamesOklahoma City$15K
- Amanda TitusOklahoma City$13K
- Michael PickrellOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.